Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →PTC Therapeutics has agreed to pay up to $268 million for Censa Pharmaceuticals, a small biotech developing the experimental phenylketonuria treatment…
PTC Therapeutics will buy privately held Censa Pharmaceuticals for up to $268 million in cash, stock, and milestone payments, the U.S. drugmaker said on…
PTC Therapeutics reported positive Phase 3 APHENITY trial data for sepiapterin in phenylketonuria, with the asset hitting both primary and secondary endpoints…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
PTC Therapeutics agreed to acquire Censa Pharmaceuticals to add Phase 3-ready CNSA-001 (sepiapterin) for PKU and BH4 pathway metabolic diseases. Deal: $10M cash + ~850,000 PTC shares (~$41M) upfront, plus up to $217.5M in development/regulatory milestones across the two most advanced programs. Phase 2 trial in PKU met primary and secondary endpoints in December 2019. OUTCOME (post-close, sourced 2026-06): The acquired asset CNSA-001/sepiapterin (developed as PTC923) won triple regulatory approval as Sephience™ — EU marketing authorization (European Commission, announced June 23, 2025; CHMP positive opinion April 25, 2025), FDA approval (July 28, 2025; NDA 219666, for sepiapterin-responsive PKU in patients 1 month and older), and Japan MHLW approval (December 22, 2025) — all based on the Phase 3 APHENITY trial. The three approvals within ~6 months confirm the 2020 deal thesis and realize the regulatory-milestone arm of the earn-out.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| PTC Therapeutics Inc. / Censa Pharmaceuticals (this deal) | 2020 | $268M | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
| AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance | 2012 | $3.5B | 77 |
| Roche Holding AG / Carmot Therapeutics Inc. | 2023 | $2.7B | 72 |
← Browse all deals · How we score deals
More: 2020 deals · Metabolic deals